Immunotherapy for Unresectable Stage III Non–Small-Cell Lung Cancer

In this issue of the Journal, Antonia and colleagues report the results of the phase 3 PACIFIC study, which evaluated the role of immune checkpoint blockade in locally advanced, unresectable, stage III non–small-cell lung cancer (NSCLC). Eligible patients had disease that had not yet progressed…

http://ift.tt/2yK1DIu